01 July 2020 3 Min Read
BioNTech vaccine shows potential in early human trials
Working with Pfizer, BioNTech says testing shows that the vaccine ‘yields immune activity and causes a strong immune response’
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In